CU20180124A7 - Derivados de aminotiazol útiles como agentes antivíricos - Google Patents

Derivados de aminotiazol útiles como agentes antivíricos

Info

Publication number
CU20180124A7
CU20180124A7 CU2018000124A CU20180124A CU20180124A7 CU 20180124 A7 CU20180124 A7 CU 20180124A7 CU 2018000124 A CU2018000124 A CU 2018000124A CU 20180124 A CU20180124 A CU 20180124A CU 20180124 A7 CU20180124 A7 CU 20180124A7
Authority
CU
Cuba
Prior art keywords
aminotiazol
derivatives
useful
agent agents
compounds
Prior art date
Application number
CU2018000124A
Other languages
English (en)
Other versions
CU24519B1 (es
Inventor
Christian Gege
Gerald Kleymann
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55701658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20180124(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of CU20180124A7 publication Critical patent/CU20180124A7/es
Publication of CU24519B1 publication Critical patent/CU24519B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

<p>La invención se refiere a nuevos compuestos de Ia Fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>con un procedimiento para su preparación y con medicamentos que comprenden dichos compuestos, en particular medicamentos antivirales. Los nuevos compuestos son adecuados como compuestos antivirales en la profilaxis y tratamiento de enfermedades o trastornos asociados a infecciones víricas, en particular infecciones víricas causadas por el virus del herpes, en particular, el virus del Herpes simplex.</p>
CU2018000124A 2016-04-06 2017-04-05 Derivados de aminotiazol útiles como agentes antivíricos CU24519B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000787 2016-04-06
PCT/EP2017/058077 WO2017174640A1 (en) 2016-04-06 2017-04-05 Aminothiazole derivatives useful as antiviral agents

Publications (2)

Publication Number Publication Date
CU20180124A7 true CU20180124A7 (es) 2019-04-04
CU24519B1 CU24519B1 (es) 2021-06-08

Family

ID=55701658

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000124A CU24519B1 (es) 2016-04-06 2017-04-05 Derivados de aminotiazol útiles como agentes antivíricos

Country Status (26)

Country Link
US (2) US10590094B2 (es)
EP (1) EP3440063B1 (es)
JP (1) JP6918823B2 (es)
KR (1) KR102354411B1 (es)
CN (1) CN109071473B (es)
AR (1) AR108175A1 (es)
AU (1) AU2017245679B2 (es)
CA (1) CA3018026C (es)
CL (1) CL2018002811A1 (es)
CO (1) CO2018010689A2 (es)
CR (1) CR20180482A (es)
CU (1) CU24519B1 (es)
EA (1) EA035401B1 (es)
EC (1) ECSP18074962A (es)
ES (1) ES2834051T3 (es)
GE (2) GEP20207128B (es)
IL (1) IL261421B2 (es)
MX (2) MX375099B (es)
MY (1) MY198018A (es)
PE (1) PE20181804A1 (es)
PH (1) PH12018501979B1 (es)
SV (1) SV2018005760A (es)
TW (1) TWI706940B (es)
UA (1) UA123734C2 (es)
UY (1) UY37193A (es)
WO (1) WO2017174640A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107118207B (zh) * 2017-05-22 2020-10-02 苏州东南药业股份有限公司 一类cdk抑制剂的制备方法
MX2020003369A (es) * 2017-10-05 2020-07-29 Innovative Molecules Gmbh Enantiomeros de tiazoles sustituidos como compuestos antivirales.
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) * 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
KR20230131177A (ko) 2020-10-29 2023-09-12 이노베이티브 몰리큘스 게엠베하 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물
EP4466255A1 (en) 2022-01-17 2024-11-27 Innovative Molecules GmbH Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
IL319024A (en) 2022-08-29 2025-04-01 Assembly Biosciences Inc Pharmaceutical preparations for the herpes virus
EP4581029A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2025111598A1 (en) 2023-11-22 2025-05-30 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
WO2026015761A1 (en) 2024-07-12 2026-01-15 Assembly Biosciences, Inc. Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy
WO2026035899A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
US20260042766A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Tricyclic compounds for treatment of hsv
WO2026035901A1 (en) 2024-08-07 2026-02-12 Assembly Biosciences, Inc. Tricyclic compounds for treatment of hsv
CN121873064A (zh) * 2024-10-17 2026-04-17 博远医药(苏州)有限公司 杂环类衍生物及其药物组合物和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
WO1997024343A1 (en) 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
CA2320167A1 (en) 1998-03-19 1999-09-23 Steven R. Turner 1,3,4-thiadiazoles useful for the treatment of cmv infections
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
EP1161423B1 (de) 1999-03-08 2004-11-10 Bayer HealthCare AG Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
CA2412720A1 (en) 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129715A1 (de) 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
MXPA06008606A (es) 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
AU2011323682B2 (en) * 2010-11-01 2016-06-23 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
GEP20207128B (en) 2020-07-10
BR112018070448A2 (pt) 2019-02-05
AR108175A1 (es) 2018-07-25
CN109071473B (zh) 2022-12-09
PE20181804A1 (es) 2018-11-19
EA201892246A1 (ru) 2019-04-30
MX2020005079A (es) 2020-08-13
IL261421B2 (en) 2025-08-01
AU2017245679A1 (en) 2018-10-04
NZ746317A (en) 2024-05-31
KR102354411B1 (ko) 2022-01-21
CL2018002811A1 (es) 2019-02-08
TWI706940B (zh) 2020-10-11
JP2019515883A (ja) 2019-06-13
EP3440063A1 (en) 2019-02-13
IL261421A (en) 2018-10-31
CR20180482A (es) 2019-04-09
ES2834051T3 (es) 2021-06-16
CN109071473A (zh) 2018-12-21
EP3440063B1 (en) 2020-08-05
WO2017174640A1 (en) 2017-10-12
CO2018010689A2 (es) 2018-10-22
CU24519B1 (es) 2021-06-08
TW201738217A (zh) 2017-11-01
IL261421B1 (en) 2025-04-01
MX2018012116A (es) 2019-05-23
US20190112285A1 (en) 2019-04-18
MY198018A (en) 2023-07-26
PH12018501979B1 (en) 2023-05-05
JP6918823B2 (ja) 2021-08-11
US10590094B2 (en) 2020-03-17
ECSP18074962A (es) 2018-11-30
EA035401B1 (ru) 2020-06-08
SV2018005760A (es) 2019-03-08
GEAP202014916A (en) 2020-02-25
UY37193A (es) 2017-11-30
PH12018501979A1 (en) 2019-07-01
KR20180132674A (ko) 2018-12-12
CA3018026C (en) 2024-06-25
UA123734C2 (uk) 2021-05-26
US20200148652A1 (en) 2020-05-14
CA3018026A1 (en) 2017-10-12
AU2017245679B2 (en) 2021-07-01
MX375099B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
CU20180124A7 (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP18069924A (es) Compuestos tetracíclicos de piridona como antivirales
MX2022012616A (es) Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
ECSP17072474A (es) Métodos para tratar infecciones por el virus filoviridae
UY35263A (es) Compuestos terapéuticos
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
CO6660514A2 (es) Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2016000278A (es) Nuevos compuestos macrocíclicos
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2019004347A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
UY35600A (es) &#34;composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas&#34;